Literature DB >> 6106888

An in vivo and in vitro evaluation of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine: an inhibitor of human lymphoblast purine nucleoside phosphorylase.

R C Willis, R K Robins, J E Seegmiller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6106888

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN： 0026-895X            Impact factor:   4.436


× No keyword cloud information.
  6 in total

1.  Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirin.

Authors:  Jim Zhen Wu; Gary Larson; Zhi Hong
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

2.  Contributions of Lesch-Nyhan syndrome to the understanding of purine metabolism.

Authors:  J E Seegmiller
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

3.  Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors.

Authors:  R F Kefford; R M Fox
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

4.  Synthesis of carbocyclic nucleoside analogs with five-membered heterocyclic nucleobases.

Authors:  Jong Hyun Cho; Steven J Coats; Raymond F Schinazi
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

5.  The pathogenesis of the Lesch-Nyhan syndrome: ATP use is positively related to hypoxanthine supply to hypoxanthine guanine phosphoribosyltransferase.

Authors:  R A Harkness; G M McCreanor; R Greenwood
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

6.  Regulation of de novo purine synthesis in human bone marrow mononuclear cells by hypoxanthine.

Authors:  M E King; J M Honeysett; S B Howell
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.